secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0001396814-25-000051
Event type: litigation
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira settles EXPAREL patent litigation; Fresenius licensed to sell generic from early 2030
--------------------------------------------------------------------------------

- Settlement with Fresenius Kabi, eVenus, Jiangsu Hengrui resolves all patent suits over EXPAREL (bupivacaine liposome).
- Fresenius gets license to sell volume-limited generic starting on confidential date in early 2030, before last patent expiry in 2044.
- Volume-limited percentages start at high-single-digit, increase to low-thirties in 2033, capped at high-thirties for final three years.
- Unlimited generic license granted no earlier than 2039.
- Pacira pays Fresenius $7 million for expected litigation cost savings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000051/0001396814-25-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000051/pcrx-20250407.htm
  HTML page:      https://secwatch.observer/filing/0001396814-25-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer